Serious adverse events · cancer patients
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 0.33 [0.02, 7.32]
Studies not reported
Very low
Participant‐reported pain relief of 50% or greater · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported pain relief of 50% or greater (substantial… compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with fibromyalgia
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
Mirtazapine showed no clear difference in tolerability: withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported sleep problems (scale: 0 to 28; higher scores… compared with placebo (low certainty).
1 finding from 1 review
Somnolence · adults with fibromyalgia
Mirtazapine may leads to higher somnolence compared with placebo (low certainty).
1 finding from 1 review
Weight gain · adults with fibromyalgia
Mirtazapine may leads to higher weight gain compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with cancer pain
Methadone may leads to higher participant‐reported pain intensity compared with morphine (low certainty).
1 finding from 1 review
Adverse events: appetite, thirst, somnolence · people with cancer pain
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review